Laboratory Corporation of America Holdings: 10-K Risk Factor Changes

2024 vs 2023  ·  SEC EDGAR  ·  2026-05-22
Other years: 2026 vs 2025 · 2025 vs 2024
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

LabCorp removed two COVID-19 pandemic-related risks that are no longer material concerns and added four new risks reflecting current business priorities, including quality standards compliance, banking relationships, capital-raising flexibility, and ESG stakeholder perception. The 12 substantively modified risks indicate heightened focus on regulatory compliance in animal research, evolving payer and insurance regulations, and operational disruption risks. These changes demonstrate a strategic shift away from pandemic-specific concerns toward longer-term operational, governance, and regulatory execution risks.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

4
New Risks
2
Removed
12
Modified
29
Unchanged
🟢 New in Current Filing The failure to establish, update, or perform to appropriate quality standards could adversely affect the Company’s business and reputation. 🔒
🟢 New in Current Filing The Company depends on a variety of U.S. and international financial institutions to provide us with banking services. The default or failure of one or more of the financial institutions that the Company relies on may adversely affect the Company's business and financial condition. 🔒
🟢 New in Current Filing The Company might not be able to engage in certain desirable capital-raising or strategic transactions. 🔒
🟢 New in Current Filing Environmental, social and governance (ESG) matters and the perception of the Company’s activities in these areas by stakeholders may impact the Company’s business and reputation. 🔒
🔴 No Match in Current Filing The effects of the outbreak of the COVID-19 pandemic could have material adverse impacts on the Company’s business, results of operations, cash flows, and financial position. 🔒
🔴 No Match in Current Filing If the Company does not respond appropriately to the ongoing COVID-19 pandemic, or if the Company’s customers do not perceive its response to be adequate, the Company could suffer damage to its reputation, which could adversely affect its business. 🔒
🟡 Modified Failure to conduct animal research in compliance with animal welfare laws and regulations could result in sanctions and/or remedies against BLS and have a material adverse effect upon the Company. 🔒
🟡 Modified Changes in payer regulations or policies, insurance regulations or approvals, or changes in laws, regulations, or policies in the U.S. or globally, including changes in their interpretation, may adversely affect the Company. 🔒
🟡 Modified Operations may be disrupted and adversely impacted by the effects of adverse weather, natural disasters, geopolitical events, public health crises, hostilities or acts of terrorism, acts of vandalism, disruption to supply chains, inaccessibility of natural resources, and other events beyond the Company's control. 🔒
🟡 Modified Cybersecurity incidents and unauthorized access to the Company's or its customers’ data could harm the Company’s reputation and adversely affect its business. 🔒
🟡 Modified Increased competition, including price competition, could have an adverse effect on the Company’s revenues and profitability. 🔒
🟡 Modified Animal populations may suffer diseases that can damage BLS's inventory, harm its reputation, or result in other liability. 🔒
🟡 Modified General or macro-economic factors in the U.S. and globally may have a material adverse effect upon the Company, and significant fluctuations in global economic conditions and an increase in the costs of goods and services could negatively impact testing volumes, drug development services, cash collections, profitability, and the availability and cost of credit. 🔒
🟡 Modified BLS’s revenues depend on the pharmaceutical, biotechnology and medical device industries. 🔒
🟡 Modified Changes in government regulation or in practices relating to the pharmaceutical, biotechnology, or medical device industries could decrease the need for certain services that BLS provides. 🔒
🟡 Modified Contract services in the drug development industry create liability risks. 🔒
🟡 Modified Damage or disruption to the Company’s facilities or operations therein could adversely affect the Company’s business. 🔒
🟡 Modified The recently completed spin-off of Fortrea may not achieve the intended results. 🔒
18 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →